The use of the epipodophyllotoxin VP 16-213 is described in twenty patients with acute myelogenous leukaemia resistant to other chemotherapy. The drug was usually given in 5-day courses of 50 mg/M2 daily and occasionally in 24-hr infusions of 250 mg/M2, on the basis of its phase-activity.
Introduction
VP 16-213 (Sandoz), a semi-synthetic derivative of the plant product podophyllotoxin, is a cytotoxic drug which a preliminary study has suggested might be active in some human malignancies including acute monocytic and myelomonocytic leukaemia (E.O.R. T.C., 1973) .
In a study ofVP by the European Organisation for Research on Treatment of Cancer, the drug was given daily for a 5-day period. Like V.M. 26, (Stahelin, 1970) , it is a phase-active compound, preventing cells from entering mitosis or killing them in pre-mitosis (Dombernowsky and Nissen, 1973) . This suggested that greater leukaemic cell kill with relative marrow sparing might be achieved by high dose infusions over a short period, as demonstrated experimentally for other cytotoxic agents (Bruce, Meeker and Valeriote, 1966) , and later applied clinically with methotrexate (Goldie, Price and Harrap, 1972) . This hypothesis is supported by experimental data in which VP 16-213 was more effective against the mouse L 1210 leukaemia when given in divided doses over a 24-hr period, than in single daily doses (Dombernowsky and Nissen, 1973) . This prompted the authors to use VP 16-213 as a high dose 24-hr infusion in some of their patients.
Patients and methods VP 16-213 was given to twenty patients with acute myelogenous leukaemia; sixteen of these had acute myeloblastic leukaemia, three acute myelomonocytic, and one acute undifferentiated leukaemia. All were in relapse, either from the time of initial presentation or after a period of remission, and all had failed to respond to conventional therapy with various combinations of cytosine arabinoside, daunorubicin, adriamycin and 6-thioguanine (Table 1) .
VP 16-213 was given to eighteen of the patients in an i.v. injection of 50 mg/M2 daily for 5 days. This was repeated at two-weekly intervals until it became obvious that the disease was continuing to progress, which in many patients was apparent after only one course. The drug is presented as a viscous water soluble fluid in 10 ml ampoules and because of the high viscosity of the drug it was necessary to dilute it to 50 ml with normal saline for ease of administration.
In four patients, VP 16-213 was given in a 24-hr infusion in a dose of 200-250 mg/M2 (i.e. the total 5-day dosage) and, in all, seven 24-hr infusions were given to these four patients (Table 2) . Initially, problems arose with drug precipitation when doses of 250 mg/M2 (total dose 300-500 mg) were dissolved in one litre of either normal saline or 5 % dextrose. Full supportive therapy during treatment, including blood and platelet transfusions and antibiotics where appropriate, was given to all patients.
Results
Two patients with acute myeloblastic leukaemia achieved complete haematological and clinical remission after treatment with VP 16-213. The first of these (Case 2, Table 1 ), achieved remission after one 5-day course of therapy, without depression of peripheral blood count. He was maintained in remission on 5-day courses at two-weekly intervals for 9 months before developing leukaemic skin infiltrates. He subsequently developed marrow relapse 11 months after the start of VP 16-213 therapy. His presenting marrow aspirate showed basophilic plasmocytoid blast cells with a low nuclear/cytoplasmic ratio and unusual appearance, but three haematologists independently confirmed a morphological diagnosis of acute myeloblastic leukaemia. No side effects were experienced from courses of maintenance treatment given at 2-weekly intervals for 9 months, except for occasional transient nausea on the first and second day of each course.
The second patient (Case 12, Table 1 ), also achieved remission after one 5-day course of therapy, with depression of blood neutrophils but not of platelets. He was maintained in remission on 5-day courses at 2-weekly intervals for 10 weeks before haematological relapse.
One patient (Case 1, Table 1 ) with acute myeloblastic leukaemia showed a partial response to VP 16-213. His marrow aspirate showed a fall in leukaemic blasts from 50 to 7% with rising peripheral platelet count after two courses of treatment, but the effect was short-lived and the marrow once more deteriorated after the third course of treatment.
None of the remaining seventeen patients showed any response to VP 16-213 therapy and in particular no response was seen to any of the seven 24-hr infusions.
In general, treatment was well tolerated with a remarkably low incidence of toxicity (Table 2) . Bone marrow depression due to VP 16-213 was rarely severe, although many patients had severely hypoplastic bone marrows before therapy, because of disease and previous treatment. A fall in neutrophil count was seen in eight patients and a fall in platelet count in four; on the other hand, the neutrophil count rose in four instances after therapy, and the platelets rose in two. It was often hard to interpret whether these results were directly attributable to VP 16-213 or to prolonged effects of previous therapy.
Nausea occurred transiently in five patients but was associated with vomiting in only one, and this was during a 24-hr infusion. Other gastro-intestinal disturbances, including oral ulceration, were not seen. Reversible alopecia occurred in one man. No disturbance in plasma electrolytes, urea, serum liver enzymes or bilirubin attributable to VP 16-213 was seen.
Discussion
This study suggests that VP 16-213 is only rarely effective in the treatment of acute myelogenous leukaemia, as a single agent given either as a course of five daily injections or in a single high dose infusion over 24 hr. It was also not possible to confirm in the three patients with acute myelomonocytic leukaemia the E.O.R.T.C. (1973) finding that the drug is particularly effective in this type ofleukaemia. Nevertheless, the complete remission obtained in one patient (Case 2, Table 1 ) was striking in that it was achieved without a significant degree of marrow suppression at any stage. This is very unusual with other current chemotherapy effective against acute myelogenous leukaemia. It was of interest that this patient had a morphologically unusual myeloblastic leukaemia.
In the dosage described, VP 16-213 rarely produced severe marrow toxicity or unpleasant side effects, in contrast to most other anti-leukaemic agents. This, despite its low remission rate, perhaps justifies the continuing use of the drug as a last resort, in that at least it is unlikely to worsen the patient's condition. There are possible ways in which the effectiveness of VP 16-213 might be improved. Firstly, the relatively moderate bone marrow toxicity suggests that the dose of the drug might be increased without life-threatening consequences, particularly if it were given as first line treatment, without a marrow made hypoplastic by previous chemotherapy. Secondly, its phase-activity and increased efficiency with scheduling in the L 1210 experimental leukaemia (Dombernowsky and Nissen, 1973) suggests that appropriate scheduling might produce better clinical effect, despite the lack of response to a 24-hr infusion in the authors' experience. Finally, VP 16-213 might be more effective used in combination or sequential chemotherapy.
